Clinical Trials Logo

Clinical Trial Summary

Kligman's trio remains the gold standard treatment for melasma. It contain hydroquinone which is an effective anti-melanogenic compound but that has poor tolerance and numerous side-effects. Thiamidol has been proven to be at least as effective as hydroquinone and has a very good safety profile. The objective of this study is to compare the Kligman's trio to the same preparation in which hydroquinone is replaced by thiamidol.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05119413
Study type Interventional
Source Centre Hospitalier Universitaire de Nice
Contact Thierry Passeron, phD
Phone +33492036488
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date November 15, 2021
Completion date November 15, 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT01976273 - A Pilot Study Testing 1064nm Q-switch Laser Versus Glycolic Acid Peels for the Treatment of Melasma N/A
Terminated NCT00863278 - Treatment of Melasma With Stabilized Kligman Preparation Associated or Not With Pulsed Dye Laser Phase 4
Recruiting NCT00927771 - Azelaic Acid Versus Hydroquinone in Melasma Phase 4
Active, not recruiting NCT01976286 - A Pilot Study Testing Salicylic Acid Peels Versus Glycolic Acid Peels for the Treatment of Melasma N/A
Not yet recruiting NCT03585179 - Oral and Topical Tranexamic Acid for the Treatment of Melasma Phase 3